发明申请
US20070082357A1 Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme
审中-公开
估计由施用化合物引起的药物不良反应的风险的方法，所述化合物本身由UGT1A1酶代谢或其代谢中间体被酶代谢
- 专利标题： Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme
- 专利标题（中）： 估计由施用化合物引起的药物不良反应的风险的方法，所述化合物本身由UGT1A1酶代谢或其代谢中间体被酶代谢
-
申请号： US11543055申请日： 2006-10-05
-
公开(公告)号： US20070082357A1公开(公告)日： 2007-04-12
- 发明人: Yoshinori Hasegawa , Yu-uichi Ando , Kaoru Shimokata
- 申请人： Yoshinori Hasegawa , Yu-uichi Ando , Kaoru Shimokata
- 申请人地址： JP Tokyo 103-0026
- 专利权人： DAIICHI PURE CHEMICALS CO., LTD
- 当前专利权人： DAIICHI PURE CHEMICALS CO., LTD
- 当前专利权人地址： JP Tokyo 103-0026
- 优先权： JP2000-376756 20001212
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68
摘要：
A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan; and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction, thereby reducing the adverse drug reaction cased by the administration of irinotecan.
信息查询
